Create a free Feed & Grain account to continue reading

ADM partners to develop bioactives

ADM and Brightseed will launch synbiotics for foods, beverages and dietary supplements by 2025.

Gergo Jaksa |
Gergo Jaksa |

ADM and Brightseed have formed a global joint partnership to develop evidence-based functional synbiotic products that target microbiome optimization with an undisclosed investment.

ADM is leveraging Brightseed’s artificial intelligence (AI) platform, Forager, to decipher the molecular interactions between dietary plants and gut microbes, and their potential impact on human health.

"We know from our recent research into global consumer trends that macro forces, including the lingering pandemic, have coincided with an increased demand for natural and plant-based solutions that target immune function, metabolic health, and mental well-being," said Mark Lotsch, ADM's president of global health and wellness. "We are thrilled to partner with Brightseed to lead in state-of-the-art discovery on the microbiome, and to bring forward science-backed solutions that empower consumers toward proactive and individualized health."

The gut microbiome is a dynamic ecosystem of microorganisms that perform complex interactions between our diet and human biology to impact health. Although scientific research over the last 15 years highlights the central role the microbiome plays on human health, details remain to be discovered about the specific functions of the diverse microbial communities and diet-microbiome-host interactions. As a result, there is a surge of interest in nutrition science on the role of synbiotics for precision gut health benefits, a category of gut health solutions in the form of food and supplements which combine probiotics (health-beneficial microbial strains) with prebiotics (non-digestible fibers that help these bacteria grow and plant substrates that microbes convert to health beneficial compounds).

Brightseed's Forager AI discovers bioactives in plants and maps them to specific modes of action at a rate and accuracy that was previously impossible, providing insights into biological changes that can occur at the cellular level.

"Brightseed and ADM share the conviction that precision health outcomes for consumers should be driving category innovation," said Sofia Elizondo, Brightseed's co-founder and chief operating officer. "ADM's advanced understanding of the untapped potential of natural compounds, combined with their vast microbial libraries, is the sum total expertise that will redefine the future of ingredients to promote a healthy microbiome."

ADM and Brightseed aim to launch highly efficacious synbiotics in specific health areas as functional ingredients for foods and beverages, dietary supplements, and medical foods by 2025.

Page 1 of 356
Next Page